Experiences with interferon-beta-1b treatment in MS after three year follow-up

Krisztina Bencsik, Cecilia Rajda, Judit Füvesi, Tamás Járđánházy, Margit Török, László Vécsei

Interferon-beta-1b (IFNβ-1b) was the first drug which has been proven to decrease the number of attacks by 34% in relapsing-remitting multiple sclerosis (MS).

The aim of this open label, observational phase IV study was to evaluate the effect of IFNβ-1b on relapse rate in a three-year follow-up. The data of the enrolled patients in the two years prior to the treatment (1995–96) served as control. The trial was carried out between 1996 and 1999. 31 patients with definite MS received 8M IU IFNβ-1b sc. every other day. The relapse rate, the duration of hospitalisation and the steroid needs for treatment of relapses were calculated. Statistical analysis was made by one-way ANOVA. At baseline the mean age was 37 ± 8 years, the mean EDSS score was 1.8 ± 1.2 and the mean duration of the disease was 4 ± 4 years. Before treatment the annual relapse rate was 1.3, while during the treatment it decreased to 0.3 (Table 1). The relapse rate was reduced by 77% compared to pre-study values (p <0.001). Before starting the therapy the patients spent 16.0 ± 2.5 days in the hospital annually. In the three years of IFNβ-1b the mean time of hospitalisation decreased by 84% (p <0.001). In the two years preceding IFNβ-1b therapy 5.7 ± 1.9 grams of methylprednisolone (MP) / patient were needed for treatment of relapses. During IFNβ-1b therapy MP needs were reduced by 75% (p <0.001).

Using the patients as their own controls is a methodological problem in MS, taking into account the more or less unpredictable course and also the fact that patients initiating treatment may do so in an active phase of the disease with consecutive spontaneous regression to the mean. Nevertheless, the magnitude of the change observed in this study supports a positive effect of IFNβ-1b on the disease under everyday practice conditions.

Correspondence:
Prof Dr László Vécsei
Department of Neurology
University of Szeged
HU-6725 Szeged
E-Mail: vecsei@nepsy.szote.u-szeged.hu

Reference
The many reasons why you should choose SMW to publish your research

**What Swiss Medical Weekly has to offer:**

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

**Editorial Board**

- Prof. Jean-Michel Dayer, Geneva
- Prof. Peter Gehr, Berne
- Prof. André P. Perruchoud, Basel
- Prof. Andreas Schaffner, Zurich (Editor in chief)
- Prof. Werner Straub, Berne
- Prof. Ludwig von Segesser, Lausanne

**International Advisory Committee**

- Prof. K. E. Juhani Airaksinen, Turku, Finland
- Prof. Anthony Bayes de Luna, Barcelona, Spain
- Prof. Hubert E. Blum, Freiburg, Germany
- Prof. Walter E. Haefeli, Heidelberg, Germany
- Prof. Nino Kuenzli, Los Angeles, USA
- Prof. René Lutter, Amsterdam, The Netherlands
- Prof. Claude Martin, Marseille, France
- Prof. Josef Patsch, Innsbruck, Austria
- Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

**Guidelines for authors:**
http://www.smw.ch/set_authors.html

---

**Impact factor Swiss Medical Weekly**

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>0.770</td>
</tr>
<tr>
<td>1996</td>
<td>1.162</td>
</tr>
<tr>
<td>1997</td>
<td>1.162</td>
</tr>
<tr>
<td>1998</td>
<td>1.162</td>
</tr>
<tr>
<td>1999</td>
<td>1.162</td>
</tr>
<tr>
<td>2000</td>
<td>1.162</td>
</tr>
<tr>
<td>2001</td>
<td>1.537</td>
</tr>
<tr>
<td>2002</td>
<td>1.537</td>
</tr>
<tr>
<td>2003</td>
<td>1.537</td>
</tr>
<tr>
<td>2004</td>
<td>1.537</td>
</tr>
</tbody>
</table>

---

**All manuscripts should be sent in electronic form, to:**

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch